Acino

Zurich, Switzerland Founded: 1836 • Age: 190 yrs Acquired By ADQ
Generic drugs are manufactured by Acino in Switzerland.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors - Brand Intelligence

About Acino

Acino is a company based in Zurich (Switzerland) founded in 1836 was acquired by ADQ in September 2021. It operates as a Direct-to-Consumer (D2C), Reseller / Distribution, and Licensing Model. Acino has completed 1 acquisition, including M8 Pharmaceuticals. Acino offers products and services including Innovative Medicines, Generic Medicines, and Manufacturing Services.

  • Headquarter Zurich, Switzerland
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Acino International Ag
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
    ADQ

    & 2 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    ADQ

    & 1 more

    (Sep 16, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Acino

Acino offers a comprehensive portfolio of products and services, including Innovative Medicines, Generic Medicines, and Manufacturing Services.

Primary

Innovative medicines are developed for various health conditions.

Generic medicines are distributed to improve healthcare access.

Manufacturing services are provided for pharmaceutical product development.

People of Acino

Headcount 1000-5000
Employee Profiles 87
Employee Profiles
People
Can Uysal
Financial Planning And Analysis Manager
People
Natalya Belousova
National Trade Marketing And E-commerce Development Manager
People
Fabio Costa
Team Lead Operational Procurement
People
Saulo Xavier
Head Of Legal, Compliance And Data Privacy Officer Latam

Unlock access to complete

Funding Insights of Acino

Investors in Acino

Acino has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ADQ, Nordic Capital and Avista Capital Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
ADQ is recognized as a leading sovereign investor focused on sustainable economic transformation in Abu Dhabi.
Founded Year Domain Location
-
Founded Year Domain Location
Private equity investments are focused on the United States market.
Founded Year Domain Location

Investments & Acquisitions by Acino

Acino has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include M8 Pharmaceuticals.

Investments
Acquisitions
Company Name Description Domain Location Founded Year Amount
Pharmaceutical company develop and commercialize leading original medicines
2007

Financial Statements - Acino

Acino Comparisons

+
Add Comparison
Available on Premium

Competitors of Acino

Latest news on Acino

Frequently Asked Questions about Acino

Acino was founded in 1836.

Acino is headquartered in Zurich, Switzerland.

Steffen Saltofte is the current CEO of Acino.

Acino is involved in the development, manufacturing, and marketing of innovative and generic medicines across various therapeutic areas. Operations are conducted in regions including Africa, Latin America, the Middle East, Türkiye, North Africa, Ukraine, and Eurasian countries. Advanced drug delivery systems are produced, focusing on dispersible and complex modified release formulations. Partnerships are established with global pharma companies for in-licensing and out-licensing of products. A commitment to sustainability and health matters is maintained through educational initiatives on conditions like hypertension and infectious diseases.

Acino offers Innovative Medicines, Generic Medicines, and Manufacturing Services.

Acino has made 1 acquisition, including M8 Pharmaceuticals.

Acino has 3 investors. Key investors include ADQ, Nordic Capital, and Avista Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available